1. Home
  2. |Insights
  3. |Ask the GAO Cyber Expert

Ask the GAO Cyber Expert

Client Alert | 1 min read | 01.30.13

On February 20 at noon at Crowell & Moring, the ABA's Public Contract Law (PCL) and Science and Technology (SciTech) Sections will co-sponsor "Information Security, Privacy and the Government Accountability Office," featuring Greg Wilshusen, GAO's top cybersecurity and privacy expert, addressing his testimony and reports to Congress on topics such as cyber threats, mobile device security, IT supply chain challenges, and critical infrastructure risks for federal agencies and government contractors. With Sharon Larkin (Chair-Elect, ABA PCL Section; GAO Contract Appeals Judge & Assistant General Counsel, Procurement Law) providing opening remarks and David Bodenheimer (C&M Partner; ABA SciTech Chair, Security, Privacy & Information Law Division) moderating, you should register here, for the opportunity to bring your best questions for Mr. Wilshusen, who has been one of the foremost thought leaders reporting and testifying on cybersecurity and privacy challenges in the public sector arena.


Contacts

Insights

Client Alert | 9 min read | 10.21.26

Artificial Intelligence in Life Sciences: Reliability of AI-Generated Evidence in Drug Discovery and Development

The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .  ...